TALARIS THERAPEUTICS INC (TALS)

US87410C1045 - Common Stock

2.78  +0.11 (+4.12%)

After market: 2.77 -0.01 (-0.36%)

News Image
3 days ago - Seeking Alpha

Talaris Therapeutics appoints current CFO Mary Kay as interim CEO (NASDAQ:TALS)

Talaris Therapeutics (TALS) put its CFO in charge on Friday, replacing a CEO Scott Requadt, who will be leaving the Company as part of a planned workforce reduction, as...

News Image
3 days ago - Talaris Therapeutics, Inc.

Talaris Therapeutics Announces Leadership Transition

BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay...

News Image
7 months ago - Talaris Therapeutics, Inc.

Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update

Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022...

News Image
7 months ago - Talaris Therapeutics, Inc.

Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company...

News Image
7 months ago - Talaris Therapeutics, Inc.

Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial

BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company...

News Image
8 months ago - Talaris Therapeutics, Inc.

Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa

BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company...

News Image
8 months ago - Talaris Therapeutics, Inc.

Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event

BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company...

News Image
9 months ago - Talaris Therapeutics, Inc.

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company...

News Image
10 months ago - Talaris Therapeutics, Inc.

Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update

All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell...

News Image
10 months ago - BusinessInsider

Nasdaq Tumbles 200 Points; McDonald's Posts Upbeat Q2 Earnings

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 200 points on Tuesday.

News Image
10 months ago - Market News Video

Tuesday 7/26 Insider Buying Report: TALS, BKR